All Stories

AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2 trial

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has hit the goals of a phase 2 rheumatoid arthritis (RA) trial.

Feb 12, 2025 - 21:03
 0
AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2 trial
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has hit the goals of a phase 2 rheumatoid arthritis (RA) trial.
Read More

Tags:

Previous Article

Oligonucleotide stops gene expansion process that drives Huntington's disease: s...

Next Article

Journey of Voyager's ALS gene therapy to clinic hindered by need to find alterna...

Related Posts

UK's Epsilogen acquires fellow immunoglobin biotech TigaTx to boost cancer antibody options

UK's Epsilogen acquires fellow immunoglobin biotech Tig...

Apr 7, 2025  0

Chutes & Ladders—J&J vet jumps to Affinia

Chutes & Ladders—J&J vet jumps to Affinia

Feb 9, 2025  0

Pfizer shakes up R&D footprint in San Diego with $255M site sale, 56 layoffs

Pfizer shakes up R&D footprint in San Diego with $255M ...

Apr 10, 2025  0